Medical technology company BD (Becton, Dickinson and Company) announced on Monday that it has launched its first high-throughput, robotics-compatible reagent kit aimed at automating large-scale, single-cell discovery studies.
By integrating Hamilton's robotics with BD's reagent kits, this solution enhances workflow efficiency, minimizes human error and accelerates research in fields like oncology and immunology. The collaboration also standardizes manual processes and speeds up the generation of material for genetic sequencing.
Featuring BD's OMICS-One XT WTA Assay and Hamilton's Microlab NGS STAR platform, the automated solution allows for seamless integration into existing laboratory workflows. Researchers worldwide can now improve consistency and throughput in genomics applications. Traditional manual DNA library construction, previously time-consuming and prone to variability, is now streamlined, reducing costs and turnaround times.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen